Secondary outcomes and qualitative findings of an open-label feasibility trial of lisdexamfetamine dimesylate for adults with bulimia nervosa

BACKGROUND: There is emerging evidence that stimulants warrant further investigation as a treatment for bulimia nervosa (BN) including a recent open-label feasibility trial examining the use of lisdexamfetamine dimestylate (LDX) for BN. The current report presents the secondary outcomes and qualitat...

Descripción completa

Detalles Bibliográficos
Autores principales: Dixon, Laura, Bartel, Sara, Brown, Victoria, Ali, Sarrah I., Gamberg, Susan, Murphy, Andrea, Brewer, Katherine L., McElroy, Susan L., Kaplan, Allan, Nunes, Abraham, Keshen, Aaron R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204259/
https://www.ncbi.nlm.nih.gov/pubmed/37218020
http://dx.doi.org/10.1186/s40337-023-00796-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204259/
https://www.ncbi.nlm.nih.gov/pubmed/37218020
http://dx.doi.org/10.1186/s40337-023-00796-x

Ejemplares similares